2018 ASCO/CAP Her2 Testing Guidelines in Breast Cancer. Impact of the Updated Guidelines on Breast Carcinomas Originally Classified as Her2 Equivocal - A Retrospective Analysis

被引：0

作者：

Alzeer, Ali ^{[1
]}

Zeck, Jay ^{[1
]}

Laureano, Julio ^{[1
]}

Sidawy, Mary ^{[1
]}

机构：

[1] MedStar Georgetown Univ Hosp, Washington, DC USA

来源：

LABORATORY INVESTIGATION | 2019年 / 99卷

关键词：

D O I：

暂无

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

108

引用

页数：2

共 50 条

[41] HER2 testing in breast cancers: comparison of assays and interpretation using ASCO/CAP 2013 and 2018 guidelines [J].

Lauren E. McLemore ;

Constance T. Albarracin ;

Stephen K. Gruschkus ;

Roland L. Bassett ;

Yun Wu ;

Sagar Dhamne ;

Isaiah Yim ;

Kevin Lin ;

Isabelle Bedrosian ;

Nour Sneige ;

Hui Chen .

Breast Cancer Research and Treatment, 2021, 187 :95-104

[42] The updated ASCO/CAP guidelines for HER2 testing create more uncertainty for clinicians [J].

Chen, J. ;

Klein, P. ;

Shao, T. .

CANCER RESEARCH, 2016, 76

[43] The Impact of 2018 ASCO-CAP HER2 Testing Guidelines on Breast Cancer HER2 Results. An audit of 2136 consecutive cases evaluated by Immunohistochemistry and In Situ Hybridization [J].

Farshid, Gelareh ;

Dhatrak, Deepak ;

Gilhotra, Amardeep ;

Koszyca, Barbara ;

Nolan, James .

LABORATORY INVESTIGATION, 2019, 99

[44] Pathological and Clinical Features Associated with Invasive Breast Cancer ISH Group 3 Classified According to the 2018 CAP/ASCO HER2 Guidelines: A Retrospective Analysis [J].

Mohamed, Nada ;

Asirvatham, Jaya .

LABORATORY INVESTIGATION, 2022, 102 (SUPPL 1) :165-166

[45] The Impact of 2018 ASCO-CAP HER2 Testing Guidelines on Breast Cancer HER2 Results. An audit of 2136 consecutive cases evaluated by Immunohistochemistry and In Situ Hybridization [J].

Farshid, Gelareh ;

Dhatrak, Deepak ;

Gilhotra, Amardeep ;

Koszyca, Barbara ;

Nolan, James .

MODERN PATHOLOGY, 2019, 32

[46] Pathological and Clinical Features Associated with Invasive Breast Cancer ISH Group 3 Classified According to the 2018 CAP/ASCO HER2 Guidelines: A Retrospective Analysis [J].

Mohamed, Nada ;

Asirvatham, Jaya .

MODERN PATHOLOGY, 2022, 35 (SUPPL 2) :165-166

[47] The impact of 2018 ASCO-CAP HER2 testing guidelines on breast cancer HER2 results. An audit of 2132 consecutive cases evaluated by immunohistochemistry and in situ hybridization [J].

Farshid, Gelareh ;

Dhatrak, Deepak ;

Gilhotra, Amardeep ;

Koszyca, Barbara ;

Nolan, James .

MODERN PATHOLOGY, 2020, 33 (09) :1783-1790

[48] Retrospective analysis of 2200 HER2 cases evaluated according to the 2013 ASCO/CAP guidelines and its correlation with the updated 2018 guideline and its impact in HER2 status [J].

Bermudez Cameo, R. I. ;

Almanzar Comas, H. P. ;

Eizaguirre Zarza, B. ;

Bakali Badesa, S. ;

Franco, J. I. ;

Viso Soriano, M. J. ;

Sobrino Prados, A. ;

Arellano Alvarez, A. ;

Estrada Mallarino, N. ;

Del Agua, C. ;

Gimeno Esteras, E. ;

Sanz Salvador, V. ;

Malo Nieves, V. .

VIRCHOWS ARCHIV, 2019, 475 :S66-S66

[49] Adherence to ASCO/CAP HER2 Testing Guidelines: Equivocal Rates and Impact on Management within a Single Institution [J].

Portier, B. P. ;

Downs-Kelly, E. ;

Lanigan, C. ;

Cotta, C. ;

Patil, D. ;

Procop, G. ;

Cook, J. R. ;

Moore, H. ;

Budd, G. T. ;

Tubbs, R. R. .

MODERN PATHOLOGY, 2011, 24 :436A-436A

[50] Adherence to ASCO/CAP HER2 Testing Guidelines: Equivocal Rates and Impact on Management within a Single Institution [J].

Portier, B. P. ;

Downs-Kelly, E. ;

Lanigan, C. ;

Cotta, C. ;

Patil, D. ;

Procop, G. ;

Cook, J. R. ;

Moore, H. ;

Budd, G. T. ;

Tubbs, R. R. .

LABORATORY INVESTIGATION, 2011, 91 :436A-436A

← 1 2 3 4 5 →